Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms

Autor: Arrigo Bondi, Nicole Brighi, Marco Paragona, Maria Abbondanza Pantaleo, Guido Biasco, Davide Campana, Giovanni Brandi, Jody Corbelli, Maria Aurelia Barbera
Přispěvatelé: Brandi, Giovanni, Paragona, Marco, Campana, Davide, Brighi, Nicole, Bondi, Arrigo, Pantaleo, Maria Abbondanza, Corbelli, Jody, Barbera, Maria Aurelia, Biasco, Guido
Rok vydání: 2017
Předmět:
Adult
Male
Oncology
medicine.medical_specialty
Nausea
medicine.medical_treatment
Unknown primary neuroendocrine neoplasm
030209 endocrinology & metabolism
Neutropenia
Disease-Free Survival
Carboplatin
03 medical and health sciences
Liver disease
0302 clinical medicine
Stomach Neoplasms
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Intestinal Neoplasms
medicine
Humans
Chemotherapy
Pharmacology (medical)
Etoposide
Aged
Retrospective Studies
Platinum
Gastroenteropancreatic neuroendocrine neoplasm
Pharmacology
High-grade neuroendocrine tumor
business.industry
Middle Aged
medicine.disease
Carcinoma
Neuroendocrine
Pancreatic Neoplasms
Regimen
Infectious Diseases
030220 oncology & carcinogenesis
Neuroendocrine carcinoma
Unknown primary
Vomiting
Neoplasms
Unknown Primary
Female
Cisplatin
medicine.symptom
business
medicine.drug
Zdroj: Journal of Chemotherapy. 30:53-58
ISSN: 1973-9478
1120-009X
Popis: To evaluate efficacy and safety of platinum and etoposide combination in the treatment of advanced gastroenteropancreatic (GEP) and unknown primary (CUP) neuroendocrine carcinomas (NEC), we analysed the records of 21 consecutive patients treated with this regimen from 1999 to 2012. Objective responses were obtained in 11 patients (52%) and disease stability (DS) in 5 (24%). Median progression-free survival (PFS) was 7 months (95% CI, 5.33–8.66). Median overall survival (OS) was 16 months (95% CI, 14.97–17.03). Patients with limited liver disease had a significantly (p = 0.002) better PFS than patients with extrahepatic disease at diagnosis with 9 months (95% CI, 7.14–10.85) vs. 4 months (95% CI, 1.60–6.40). Two patients experienced durable complete response (30 and 90 months). The most common grade 3–4 toxicities were neutropenia (61%), anaemia (50%), nausea and vomiting (27%) and fatigue (22%). The platinum plus etoposide regimen has an acceptable toxicity profile and is effective in patients with GEP and CUP-NECs.
Databáze: OpenAIRE
Externí odkaz: